narcolepsy
Information
- Disease name
- narcolepsy
- Disease ID
- DOID:8986
- Description
- "A sleep disorder that involves an excessive urge to sleep at inappropriate times, such as while at work." [url:http\://en.wikipedia.org/wiki/Narcolepsy]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01394614 | Completed | Risk of Narcolepsy Associated With Administration of H1N1 Vaccine | June 2011 | November 2014 | |
| NCT00049803 | Completed | Phase 3 | Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients | December 2000 | April 2004 |
| NCT00066170 | Completed | Phase 3 | Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy | April 2003 | November 2004 |
| NCT00078312 | Completed | Phase 3 | Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder | January 2004 | July 2006 |
| NCT00078377 | Completed | Phase 3 | Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy | March 2004 | January 2005 |
| NCT00107796 | Completed | Phase 3 | Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy | October 2004 | September 2005 |
| NCT00107848 | Completed | Phase 3 | PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome | October 2004 | September 2005 |
| NCT00132873 | Completed | Phase 3 | Trial of Xyrem® (Sodium Oxybate) for the Treatment of Narcolepsy | October 2004 | December 2007 |
| NCT00174174 | Completed | N/A | Provigil (Modafinil) Study by Taiwan Biotech Co. | September 2003 | |
| NCT00214968 | Completed | Phase 3 | Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness | January 2005 | October 2005 |
| NCT00228553 | Completed | Phase 3 | Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness | May 2004 | July 2006 |
| NCT00228566 | Completed | Phase 3 | Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome | October 2005 | July 2006 |
| NCT00244465 | Completed | Observational Study to Evaluate Risks of Side Effects, Drug Abuse and Dependence in Patients Who Received Xyrem ® on Prescription | May 2006 | September 2016 | |
| NCT00283894 | Completed | Body Weight Regulation in Patients With Narcolepsy | January 20, 2006 | June 19, 2013 | |
| NCT02785328 | Completed | N/A | Sleep and Memory in Children | February 2016 | May 29, 2018 |
| NCT02806908 | Completed | Phase 2 | Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy | June 2016 | May 19, 2019 |
| NCT02821715 | Completed | Phase 2 | Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients | September 2016 | February 2019 |
| NCT02832336 | Completed | Phase 1/Phase 2 | The Effect of Caffeine on the Narcoleptic Patients | October 1, 2016 | May 7, 2018 |
| NCT02913651 | Completed | Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia | January 2016 | December 2016 | |
| NCT03173378 | Completed | Evaluation of Academic and Professional Trajectories of Narcoleptic Patients | October 3, 2017 | July 10, 2018 | |
| NCT03267303 | Completed | Phase 2 | A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy | October 31, 2017 | August 8, 2019 |
| NCT03378453 | Completed | N/A | Narcolepsy Protect Against Alzheimer's Disease? | April 7, 2016 | November 2017 |
| NCT03748979 | Completed | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy | November 21, 2018 | October 24, 2019 |
| NCT03765892 | Completed | Study of the Academic and Professional Course of Narcoleptic Patients (NARCOSCOL-NARCOVITAE) | February 27, 2020 | February 27, 2023 | |
| NCT03881852 | Completed | Phase 2 | Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT) | January 30, 2019 | November 27, 2019 |
| NCT03904238 | Completed | N/A | Psychosocial Adjunctive Treatment for Hypersomnia (PATH) | December 10, 2018 | October 7, 2019 |
| NCT04072380 | Completed | Phase 2 | A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy | September 21, 2019 | June 13, 2023 |
| NCT04141891 | Completed | N/A | Advancing Understanding of Transportation Options | December 12, 2019 | December 21, 2023 |
| NCT04232644 | Completed | Phase 1 | Pilot Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Abuse Liability of an Abuse-Deterrent Immediate-Release Formulation (ADAIR) | May 27, 2019 | July 17, 2019 |
| NCT04306952 | Completed | N/A | Awareness and Self-Compassion Enhancing Narcolepsy Treatment | June 15, 2020 | June 30, 2022 |
| NCT04316286 | Completed | N/A | TElemedicine for NARcolepsy | April 1, 2020 | May 31, 2023 |
| NCT04451668 | Completed | Phase 3 | An Open Label Study of FT218 in Subjects With Narcolepsy | June 12, 2020 | December 22, 2023 |
| NCT04647903 | Completed | Phase 1 | Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR) | October 5, 2020 | December 17, 2021 |
| NCT04667338 | Completed | A Study to Collect Information of People With Narcolepsy in Spain | February 24, 2021 | November 3, 2022 | |
| NCT04794491 | Completed | Phase 4 | An Interventional Safety Switch Study (Segue Study) of XYWAV in Narcolepsy | March 22, 2021 | November 15, 2022 |
| NCT04803786 | Completed | A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy | April 9, 2021 | February 24, 2022 | |
| NCT04827329 | Completed | Anesthetic Management of Patients With Chronic Sleep Disorders | March 1, 2021 | July 1, 2021 | |
| NCT04923594 | Completed | Phase 2 | Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy | September 13, 2021 | June 30, 2022 |
| NCT05008341 | Completed | Phase 1 | Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration | August 27, 2021 | April 15, 2022 |
| NCT05015673 | Completed | Phase 1 | This is a Study to Determine the Effect of Multiple Doses of an Investigational Drug, Taken by Mouth, in People With Narcolepsy-cataplexy. Accepting Both Males and Females Ages of 18 Years to 55 Years. This Study Will be Conducted in the US and Will Require Approximately 13 Weeks Participation. | June 5, 2014 | May 26, 2015 |
| NCT05055024 | Completed | Phase 2 | An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy | October 26, 2021 | January 19, 2023 |
| NCT05059223 | Completed | Phase 3 | A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy | September 15, 2021 | March 15, 2024 |
| NCT05709873 | Completed | N/A | Narcolepsy Nightmare Study | February 22, 2023 | April 30, 2024 |
| NCT00424931 | Completed | Phase 2 | A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy | January 2007 | December 2007 |
| NCT00916253 | Completed | N/A | Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies | March 2010 | August 2012 |
| NCT01006122 | Completed | Phase 2 | A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy | November 2009 | November 2010 |
| NCT01067222 | Completed | Phase 3 | Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy | May 2009 | December 2010 |
| NCT01067235 | Completed | Phase 3 | Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy | October 2009 | July 2010 |
| NCT01146600 | Completed | Phase 2 | Clarithromycin for the Treatment of Hypersomnia | July 2010 | September 2012 |
| NCT00001664 | Completed | Sleep Disorders of Patients With Diseases of the Nervous System | December 4, 1996 | September 7, 2011 | |
| NCT01399606 | Completed | Phase 3 | Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant) | May 2011 | September 2016 |
| NCT01485770 | Completed | Phase 2 | A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness | December 2011 | May 2012 |
| NCT01624480 | Completed | Phase 1 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy | July 2012 | December 2015 |
| NCT01681121 | Completed | Phase 2 | A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy | September 2012 | August 2013 |
| NCT01719315 | Completed | Neurophysiologic Correlates of Hypersomnia | November 2012 | June 2018 | |
| NCT01789398 | Completed | Phase 3 | Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV) | September 2012 | August 2014 |
| NCT02348593 | Completed | Phase 3 | "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" | May 2015 | February 2017 |
| NCT02348632 | Completed | Phase 3 | "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA" | May 2015 | December 2017 |
| NCT02720744 | Completed | Phase 3 | Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy | November 17, 2016 | March 25, 2020 |
| NCT02769780 | Completed | A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy | July 8, 2015 | August 9, 2021 | |
| NCT04940806 | Enrolling by invitation | The Value of Combined Detection of Orexin-A, HLA Gene, PSG and MSLT in the Evaluation of Patients With Narcolepsy | May 1, 2021 | June 2025 | |
| NCT05113745 | Enrolling by invitation | Phase 3 | A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy | October 20, 2021 | December 2024 |
| NCT05371483 | Enrolling by invitation | Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments | May 18, 2022 | July 2026 | |
| NCT05530447 | No longer available | Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy | |||
| NCT05870735 | Not yet recruiting | Discovering Factors in Narcolepsy Patients' Clinical Research Experiences | June 2024 | June 2026 | |
| NCT06383806 | Not yet recruiting | N/A | Decreasing Nightmares in Adults With Narcolepsy | July 2024 | September 2026 |
| NCT05536011 | Recruiting | WAKIX® (Pitolisant) Pregnancy Registry | August 24, 2021 | June 30, 2030 | |
| NCT05884112 | Recruiting | N/A | Treating Comorbid Depression of Patients With Narcolepsy by Intermittent Theta Burst Stimulation | February 22, 2023 | June 2025 |
| NCT06179407 | Recruiting | Phase 1 | Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004) | January 24, 2024 | December 5, 2024 |
| NCT06279247 | Recruiting | Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy | September 1, 2022 | September 2024 | |
| NCT05321355 | Recruiting | Mainz Register of Patients With Sleep Disorders | February 1, 2022 | January 31, 2030 | |
| NCT04330963 | Recruiting | International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study | January 6, 2020 | June 30, 2026 | |
| NCT05615584 | Recruiting | N/A | Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence | February 15, 2023 | October 30, 2025 |
| NCT06413420 | Recruiting | SUNOSI® (Solriamfetol) Pregnancy Registry | July 31, 2019 | September 2029 | |
| NCT05773872 | Recruiting | N/A | Evaluation of Social Cognition in Patient With Type 1 or Type 2 Narcolepsy Versus Patients With Idiopathic Hypersomnia | March 7, 2023 | March 2025 |
| NCT05869773 | Recruiting | Phase 4 | A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy | June 26, 2023 | July 1, 2025 |
| NCT04899947 | Recruiting | Child and Adolescent Registry for Participants With Narcolepsy | October 10, 2020 | October 1, 2024 | |
| NCT05875974 | Recruiting | Phase 4 | Ph4 PSG Combined JZP258-407 | July 27, 2023 | November 1, 2024 |
| NCT04419792 | Suspended | 'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy' | October 15, 2019 | September 30, 2020 | |
| NCT01792583 | Terminated | The Nuvigil and Provigil Pregnancy Registry | June 30, 2009 | November 30, 2023 | |
| NCT00366080 | Terminated | Phase 2 | Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy | November 2006 | January 2008 |
| NCT05373979 | Unknown status | Development and Validation of Pediatric Narcolepsy Patient Reported Outcomes Scale | April 2, 2019 | April 30, 2023 | |
| NCT03425214 | Unknown status | N/A | Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Behavior Disorder | January 19, 2018 | June 30, 2019 |
| NCT02799849 | Unknown status | N/A | Metabolism Characteristics in the Children With Narcolepsy | December 20, 2013 | November 2019 |
| NCT00484757 | Unknown status | N/A | Effect of Intranasal Administration of Orexine A on IL-6-System, Sleep-Wake-Regulation and Neurocognition | June 2007 | August 2009 |
| NCT03376568 | Unknown status | Investigation of Clinical Feature and Brain Function in Narcoleptic Patients | January 28, 2016 | December 30, 2019 | |
| NCT02077036 | Unknown status | N/A | Narcolepsy - New Potential Treatment | ||
| NCT05627388 | Withdrawn | N/A | Feasibility Study of At-Home EEG Monitoring for Hypersomnia | February 2023 | April 1, 2024 |
| NCT03626727 | Withdrawn | Early Phase 1 | Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia | September 2020 | September 1, 2020 |
- Disase is a (Disease Ontology)
- DOID:535
- Cross Reference ID (Disease Ontology)
- GARD:7162
- Cross Reference ID (Disease Ontology)
- ICD10CM:G47.41
- Cross Reference ID (Disease Ontology)
- ICD9CM:347.0
- Cross Reference ID (Disease Ontology)
- MESH:D009290
- Cross Reference ID (Disease Ontology)
- MIM:161400
- Cross Reference ID (Disease Ontology)
- MIM:605841
- Cross Reference ID (Disease Ontology)
- MIM:609039
- Cross Reference ID (Disease Ontology)
- MIM:612417
- Cross Reference ID (Disease Ontology)
- MIM:612851
- Cross Reference ID (Disease Ontology)
- MIM:614223
- Cross Reference ID (Disease Ontology)
- MIM:614250
- Cross Reference ID (Disease Ontology)
- NCI:C84489
- Cross Reference ID (Disease Ontology)
- ORDO:2073
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:155059003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0027404
- Exact Synonym (Disease Ontology)
- Narcolepsy, without cataplexy
- Exact Synonym (Disease Ontology)
- paroxysmal sleep
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0030050
- OMIM Phenotype Series Number (OMIM)
- PS161400
- MeSH unique ID (MeSH (Medical Subject Headings))
- D009290